Business Description
TG Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US88322Q1085
Share Class Description:
TGTX: Ordinary SharesDescription
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.72 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.89 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.64 | |||||
| Beneish M-Score | 30.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 119 | |||||
| 3-Year EBITDA Growth Rate | 9.9 | |||||
| 3-Year EPS without NRI Growth Rate | 9.4 | |||||
| 3-Year FCF Growth Rate | 4.7 | |||||
| 3-Year Book Growth Rate | 4.3 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.27 | |||||
| 9-Day RSI | 75.95 | |||||
| 14-Day RSI | 75.11 | |||||
| 6-1 Month Momentum % | -62.77 | |||||
| 12-1 Month Momentum % | 31.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.53 | |||||
| Quick Ratio | 4.95 | |||||
| Cash Ratio | 2.62 | |||||
| Days Inventory | 1763.16 | |||||
| Days Sales Outstanding | 41.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.2 | |||||
| Shareholder Yield % | 0.19 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.69 | |||||
| Operating Margin % | -9.98 | |||||
| Net Margin % | -13.65 | |||||
| FCF Margin % | -22.17 | |||||
| ROE % | -33.07 | |||||
| ROA % | -11.16 | |||||
| ROIC % | -36.55 | |||||
| ROC (Joel Greenblatt) % | -41.57 | |||||
| ROCE % | -7.33 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 68.49 | |||||
| PS Ratio | 12.73 | |||||
| PB Ratio | 14.45 | |||||
| Price-to-Tangible-Book | 14.45 | |||||
| EV-to-EBIT | -174.09 | |||||
| EV-to-EBITDA | -180.52 | |||||
| EV-to-Revenue | 11.8 | |||||
| EV-to-Forward-Revenue | 10 | |||||
| EV-to-FCF | -53.21 | |||||
| Price-to-Net-Current-Asset-Value | 15.57 | |||||
| Earnings Yield (Greenblatt) % | -0.57 | |||||
| FCF Yield % | -1.77 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TGTX
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TG Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 189.772 | ||
| EPS (TTM) ($) | -0.28 | ||
| Beta | 2.34 | ||
| Volatility % | 119.39 | ||
| 14-Day RSI | 75.11 | ||
| 14-Day ATR ($) | 0.954873 | ||
| 20-Day SMA ($) | 12.9 | ||
| 12-1 Month Momentum % | 31.59 | ||
| 52-Week Range ($) | 6.46 - 35.67 | ||
| Shares Outstanding (Mil) | 151.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TG Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TG Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
TG Therapeutics Inc Frequently Asked Questions
What is TG Therapeutics Inc(TGTX)'s stock price today?
The current price of TGTX is $15.72. The 52 week high of TGTX is $35.67 and 52 week low is $6.46.
When is next earnings date of TG Therapeutics Inc(TGTX)?
The next earnings date of TG Therapeutics Inc(TGTX) is 2024-02-28 Est..
Does TG Therapeutics Inc(TGTX) pay dividends? If so, how much?
TG Therapeutics Inc(TGTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers